Teva Falls Further Behind AZ, Sanofi With Phase III Subcutaneous Cinqair Failure
Executive Summary
Teva has hit a stumbling block in its attempt to catch up with rivals and develop a subcutaneous version of its asthma therapy Cinqair with the failure of two Phase III studies.